News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
CARMAT SAS Sets $89.81 Million IPO to Fund Artificial Heart on July 13
July 8, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS, July 7 (Reuters) - French artificial heart developer Carmat, which counts EADS (EAD.PA) amongst its shareholders, has set the date of its initial public offering for July 13 as it seeks extra funds to bring its product to market.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
Mergers & acquisitions
UPDATE: Novo Nordisk Seeks To Steal Metsera From Pfizer With $8.5B Offer
October 30, 2025
·
4 min read
·
Annalee Armstrong
Earnings
Novartis CEO Says Trump’s Drug Pricing Deals Don’t Address Root Problem
October 28, 2025
·
3 min read
·
Annalee Armstrong
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
October 26, 2025
·
2 min read
·
Heather McKenzie
Immunology and inflammation
Biogen Grows Immunology Pipeline With Vanqua’s Anti-Inflammatory Molecule
October 24, 2025
·
2 min read
·
Dan Samorodnitsky